医学
角膜新生血管
阿柏西普
眼科
新生血管
角膜
视力
脉络膜新生血管
外科
贝伐单抗
内科学
化疗
血管生成
作者
Ruti Sella,Meydan Ben Ishai,Eitan Livny,Yoav Nahum,Irit Bahar
出处
期刊:Eye & Contact Lens-science and Clinical Practice
[Ovid Technologies (Wolters Kluwer)]
日期:2020-05-14
卷期号:47 (4): 180-184
被引量:7
标识
DOI:10.1097/icl.0000000000000709
摘要
Purpose: To evaluate the effect of a single subconjunctival aflibercept injection on formed corneal neovascularization. Methods: A prospective clinical trial, conducted at a single tertiary medical center. Included were consecutive patients with corneal pathologies complicated by corneal neovascularization, who were candidates for anti–vascular endothelial growth factor treatment at the discretion of a cornea specialist. A single subconjunctival injection of 0.08 mL of Aflibercept (Eylea 25 mg/mL) was administered near the limbus in proximity to the areas of maximal pathological neovascularization. Follow-up visits were scheduled on days 7, 30, 60, and 90 following injection. Best-corrected visual acuity (BCVA), intraocular pressure, slitlamp examination, digital cornea photography, specular microscopy, and anterior-segment optical coherence tomography were documented at each visit. The images were graded by a masked observer for density, extent, and centricity of corneal vascularization. Results: Six eyes of six patients were analyzed. No clinically significant ocular or systemic adverse events were documented. No change was noted in extent, density, or centricity of corneal blood vessels at seven, 30, and 90 days after injection ( P >0.1 for all time point comparisons, Friedman test). Best-corrected visual acuity fluctuated insignificantly in 5/6 patients during follow-up time, and objective but not subjective improvement of BCVA was noted in one patient with no concurrent change of neovascularization. The recruitment has therefore halted prematurely. Conclusions: A single subconjunctival aflibercept injection seems to be well tolerated. However, it is ineffective for regressing formed corneal neovascularization.
科研通智能强力驱动
Strongly Powered by AbleSci AI